The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRSN | -51.59% | -95.29% | -45.7% | -92% |
| S&P | +12.66% | +85.37% | +13.13% | +181% |
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
The company reported disappointing clinical results.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.01M | -12.6% |
| Gross Profit | $10.93M | -10.4% |
| Gross Margin | 99.25% | 2.4% |
| Market Cap | $38.73M | -83.3% |
| Market Cap / Employee | $0.38M | 0.0% |
| Employees | 102 | -17.1% |
| Net Income | -$7.55M | 34.4% |
| EBITDA | -$7.37M | 36.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $56.87M | -27.9% |
| Accounts Receivable | $0.17M | -83.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $2.29M | -84.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.36% | -25.8% |
| Return On Invested Capital | -618.71% | -498.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.19M | 62.8% |
| Operating Free Cash Flow | -$3.19M | 62.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -17.39 | -1.39 | -0.69 | -0.73 | -100.33% |
| Price to Sales | 4.36 | 1.26 | 1.06 | 1.17 | -82.46% |
| Price to Tangible Book Value | 4187.31 | -104.66 | -29.88 | -0.73 | -100.11% |
| Enterprise Value to EBITDA | -4.91 | 1.45 | 0.98 | 2.15 | -123.15% |
| Return on Equity | -292.2% | -213.3% | -280.3% | -505.1% | 89.74% |
| Total Debt | $28.65M | $24.62M | $20.62M | $2.29M | -92.72% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
